• Tuberculosis and Respiratory Diseases
• /
• 제45권5호
• /
• pp.1087-1093
• /
• 1998

Mucormycosis is the common name given to several different diseases caused by fungi of the order Mucorales. The mucoraceae are ubiquitous fungi and are common inhabitants of decaying matter. In contrast to the widespread distribution of these fungi, disease in humans is limited, in most cases, to people with severe immunocompromised, diabetes mellitus, or trauma. 1be fungus gains entry to the body through the respiratory tract. The spores are presumably deposited in the nasal turbinates and may be inhaled into the pulmonary alveoli. The manifestations of mucormycosis are rhinocerebral, pulmonary, cutaneous, gastrointestinal, central nervous system, and miscellaneous. Sporadic reports can be found of mucormycosis involving other areas : heart, bones, kidney, bladder, mediastinum, and trachea. However, isolated tracheal mucormycosis is very rare. Therefore, we report a 57-year old, noninsulin dependent diabetic woman who presented with acute, severe degree of upper airway obstruction due to isolated mucormycosis of the trachea.

• 디지털융복합연구
• /
• 제14권7호
• /
• pp.309-319
• /
• 2016

보건의료데이터의 질적 수준을 향상시키기 위해서는 데이터 질 관리 알고리즘을 개발할 필요성이 있다. 이에 본 연구에서는 질환의 유병률, 입원율이 높은 고혈압 환자의 당뇨질환 동반에 관련된 데이터 질 관리 알고리즘을 개발하고자 하였다. 이를 위해 2011년, 2012년 퇴원손상심층조사 자료 중 고혈압 환자 61,199건을 추출하여 분석대상으로 하였다. 데이터 마이닝의 대화식 의사결정나무 방법과 Outlier Detection 방법론을 통해 데이터 질 관리 알고리즘 개발한 결과 고혈압 환자가 당뇨병을 동반상병으로 가지는데 영향을 미치는 요인으로는 성별, 연령, 당뇨병성 사구체 장애, 당뇨병성 망막병증, 당병성 다발성 신경병증 등이 있었다. 의사결정나무 결과에 따라 당뇨병을 동반상병으로 가질 확률 값이 80% 이상이거나, 20% 이하인 집단을 Outlier(극단치)로 정의하고, 고혈압 환자의 당뇨 동반에 대한 극단치를 가지는 6개 집단을 발견하였다. 이와 같이 Outlier(극단치) 집단에 포함되는 실제 데이터를 확인하여 데이터의 질적 수준을 향상 시킬 필요가 있다.

• 동의생리병리학회지
• /
• 제21권5호
• /
• pp.1163-1169
• /
• 2007

Effects of Sotosaja hwan on Blood Glucose, Hyperlipidemia, Polyol Pathway and Antioxidative Mechanism in ob/ob Mouse Diabetes is a disease in which the body does not produce or properly use insulin. Etiological studies of diabetes and its complications showed that oxidative stress might play a major role. Therefore, many efforts have been tried to regulate free oxygen radicals for treating diabetes and its complications. Sotosaja-hwan has been known to be effective for the antiaging and composed of four crude herbs. In male ob/ob mouse in severe obesity, hyperinsulinemia and hyperlipidemia, which are features of NIDDM, the hyperglycemic activites and mechanisms of Sotosaja-hwan were examined. Mice were grouped and treated for 5 weeks as follows. Both the lean (C57/BL6J black mice) and diabetic (ob/ob mice) control groups received standard chow. The experimental groups were fed with a diet of chow supplemented with 30 and 90 mg Sotosaja-hwan per 1 kg of body weight for 14 days. The effects of Sotosaja-hwan extract on the ob/ob mice were observed by measuring the serum levels of glucose, insulin, lipid components, and the kidney levels of superoxide anion radical $({\cdot}O_2)$, MDA+HAE, GSH/GSSG ratio, and also the enzyme activities involved in polyol pathway. Sotosaja-hwan lowered the levels of serum glucose and insulin in a dose dependent manner. Total cholesterol, triglyceride and free fatty acid levels were decreased, while the HDL-cholesterol level was increased, in Sotosaja-hwan treated groups. Renal aldose reductase and sorbitol dehydrogenase activities were increased in the ob/ob mice, whereas those were inhibited in the Sotosaja-hwan-administered groups. Sotosaja-hwan inhibited the generation of ${\cdot}O_2$ in the kidney. Finally, MDA+HAE levels was increased and GSH/GSSG ratio was decreased in the ob/ob mice, whereas those were improved in the Sotosaja-hwan-administered groups. Sotosaja-hwan showed the antidiabetic and anti hyperlipidemic activities by regulating the activities of polyol pathway enzymes, scavenging reactive oxygen species and reducing the MDA+HAE levels in the ob/ob mice.

• 한국임상약학회지
• /
• 제21권4호
• /
• pp.364-375
• /
• 2011

Given that single blockade with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) can achieve only partial and undurable suppression of the Renin Angiotensin System (RAS), it has been hypothesized that dual blockage would be more beneficial in the management of blood pressure (BP) reduction and prevention of progressive chronic kidney disease (CKD) than either agent alone. Thus, it has been suggested that the combination of an ACEI and an ARB might provide renal benefits to hypertensive patients over and above BP reduction. However, this might also expose patients to additive or synergistic side effects. We attempted to conduct a systematic review to evaluate the benefits and harms of combination therapy in hypertensive patients with or without kidney diseases. MEDLINE and KoreaMed were searched for relevant randomized clinical trials in adult hypertensive patients with or without diabetes (restricted to 1997, limited to trials published in English). Results were summarized using the random-effects model, and between-studies heterogeneity was estimated with $I^2$. A final analysis of ten trials (23,928 patients) revealed that the combination of an ACEI and an ARB reduced blood pressure (SBP/DBP) by 3.95/2.02 mmHg (95% confidence interval [CI], -4.38 to -3.53/-2.33 to -1.71) compared with ACEI monotherapy, and 2.83/2.64 mmHg (95% CI, -3.25 to -2.41/-4.95 to -0.33) compared with ARB monotherapy. Eight trials (391 patients) demonstrated a significant reduction in 24h-proteinuria (weighted mean difference, 0.16 g/day, 95% CI, -0.26-0.05), but they did not translate into an improvement in GFR. Tests for heterogeneity showed no difference in effect among the studies. The combination therapy reduced proteinuria by 30% (95% CI, 23% to 37%) and 39% (95% CI, 31% to 48%) compared with ACEI monotherapy and ARB monotherapy, respectively. However, in patients who had proteinuria more than 0.5 g/day, the combination therapy failed to show significant reduction in urinary protein excretion. The current cumulative evidence suggests that diabetic patients with proteinuria on dual RAS blockade have an increase risk of adverse events such as hyperkalemia, hypotension, and so on, compared with ACEI or ARB alone. It is, therefore, proposed that the combination therapy should not be routinely used for the treatment of hypertension with or without compelling indications.

• 동의생리병리학회지
• /
• 제30권3호
• /
• pp.164-176
• /
• 2016

This study was perfomed to investigate the effects of Chunghyul-plus(CHP) on oxidative damage and hyperlipidemia in db/db mouse. After treatment with CHP, safety in cytotoxicity, heavy metal toxicity, production of reactive oxygen species(ROS), nitric oxide (N0) and proinflammatory cytokine IL-Ib, TNF-a, IL-6 in RAW 264.7 cells. Serum total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, insulin, GLP-1, glucose, food intake, body weight, organ weight, AST, ALT, ALP, BUN, creatine and histologic change of liver and aorta were measured in db/db mouse after oral administration of CHP. CHP showed safety in cytotoxicity and toxicity of liver and kidney for logn time administration. CHP increased the DPPH and ABTS radical scavenging activity. CHP showed significant inhibitory effect on reactive oxygen species (ROS), and showed inhibitory effect on nitiric oxide(NO) compared to control group. CHP decreased cytokine IL-6 production significantly, and decreased IL-1β and TNF-α compared to control group. CHP decreased body and organ weitht, intake food, and glucose levels compared to control group. CHP decreased total cholesterol and triglyceride significantly, and decreased LDL-cholesterol levels and increased HDL-cholesterol levels compared to control group. CHP decreased atherogenic index and cardiac risk factor significantly. CHP increased serum insulin and GLP-1 compared to control group. In histologic examination, lipophagy in the liver and aorta decreased in CHP treated mice and the cell was regular and boundary of vessel wall was clear compared to control group. These results suggest that CHP is effective in antioxidation activity and treatment and prevention of hyperlipidemia, atherosclerosis, diabetes, ischemic heart disease, stroke and other cardiocerebrovascular disease.

• Radiation Oncology Journal
• /
• 제8권1호
• /
• pp.85-93
• /
• 1990

1989년 보건사회부 통계에 의하면 1988년도 한국 성인 남녀의 제일 많은 암 사망원인은 위암으로 밝혀졌다. 위암의 최신의 치료방법은 조기발견에 의한 근치절제술이지만 수술 후 잔존위암, 재발성 위암 및 절제 불가능한 위암의 치료는 난점으로 지적되어 있다. 저자는 1895년 11월부터 1988년 12월까지 메리놀병원 치료방사선과에서 치료를 받았던 36예중 분석이 가능한 25예를 대상으로 다음과 같은 결론을 얻었다. 1, 방사선치료, 복합 항암제 치료, 및 온열치료의 병용요법은 비교적 안전하였으며 병용요법의 독성에 의한 사망은 없었다. 2, 병용요법에 의한 객관적 반응의 결과는 종괴축소로 판별하였으며 종괴절제술을 시행하였던 3예를 제외한 22예에서 측정이 가능하였다. 종괴의 완전 소실을 보인 예는 없었으며 11예($50\%$)에서 $50\%$이상의 종괴 축소를 보였다. 그러나 주관적 반응으로 증상의 소실 혹은 완화를 보인 예는 18예 ($82\%$)이었다. 3, 총 방사선조사 선량과 온열치료시 도달된 최고 온도는 종양반응의 예후 예측인자로 확인되었다. 4000 cGy 이상 조사된 14예중 9예 ($64\%$)에서 부분 반응을 보였으나 4000 cGy 미만의 4예중 1예 ($25\%$)에서 부분반응을 보였다. 온열치료시 도달된 최고 온도가 $41^{\circ}C$ 미만인 8예증 2예 ($25\%$), $41^{\circ}C$ 이상인 12예중 8예 ($67\%$)에서 부분 반응을 보였다. 4, 25예중 3예 ($12\%$)는 현재 생존하고 이중 1예는 절제 불가능했던 위암 환자로 5980 cGy의 방사선치료만 받았던 예로 현재 35개월째 생존하고 있으나 최근 원발 병소의 진행과 원격 전이가 관찰되었다. 나머지 2예는 근치절체술 후 절단면에서 암세포 침윤이 관찰되었던 예로 1예는 방사선치료와 온열치료, 1예는 복합 항암제치료는 시행받았으며 전자는 35개월, 후자는 24개월째 무병 상태로 생존하고 이다. 반응정도에 따른 정중 생존기간은 무반응군은 4.6개월 반응군은 11.5개월이었다.

• 한국임상수의학회지
• /
• 제27권4호
• /
• pp.348-365
• /
• 2010

Artemisia capillaries THUNB is a perennial herb that belongs to the family compositae spp. and the most common plant among the various herbal folk remedies used in treatment of abdominal pain, hepatitis, chronic liver disease, jaundice and coughing in Korea. The object of this study is to observe the dosage-dependent anti-obestic effects of an aqueous extracts of dried aqueous extracts of stems of Artemisia capillaris Thunberg. [Artemisiae capillaris Herba, In-Jin in Korean, INJ] on 45%/Kcal high fat diet (HFD) supplied mice. 45%/Kcal rodent HFD are supplied to ICR mice from 1 week before initiation of INJ administration throughout the 12 weeks, and after the end of 12 weeks of 62.5, 125 and 250 mg/kg/day of INJ administration, the efficacy was divided into five categories 1) hypoglycemic, 2) hepato-protective, 3) nephroprotective, 4) hypolipemic, and 5) anti- obesity effects. The effects were compared to those of simvastatin (for hypolipemic activity), silymarin (for hepatoprotective and free radical scavenger effects) and metformin (for hypoglycemic and related anti-obesity effects). 7 animals per group (8 groups; total 56adapted mice on HFD were selected base on the body weight at 6 days after initiation of HFD supply) were used in this experiment. INJ and all three different reference drugs were directly suspended or dissolved in distilled water, and administered at a volume of 10 mL/kg, once a day for 84 days from 1 week after HFD supply. As results of 91 days of continuous HFD supply, mice showed marked obese states, hyperglycemia, hyperlipemia, liver damages and kidney damages. These mean the obesity, diabetes, diabetic hepatopathies, nephropathies and hyperlipemia were induced by HFD supply. After end of 84 days of continuous treatment of three different dosages of INJ, all diabetes related complications were inhibited; relatively favorable anti-obesity, hypolipemic, hepatoprotective, hypoglycemic and nephroprotective effects. These favorable effects showed relatively good dose-relations between all three different dosages of INJ treated, and INJ 250 mg/kg showed enough favorable effects on diabetes and related four complications tested as compared with one of each three different references. Otherwise, the efficacy of 62.5 and 125 mg/kg of INJ was somewhat slighter than those of all three reference drugs. Therefore, the suitable effective dosage of INJ is considered as 250 mg/kg/day in the present study. The overall anti-obesity effects of INJ 250 mg/kg-treated group was similar or more favorable than those of metformin 250 mg/kg-treated group, and INJ 250 mg/kg showed slighter hypoglycemic effects with silymarin 100 mg/kg and metformin 250 mg/kg, similar hypolipemic effects with simvastatin 10 mg/kg, and similar hepatoprotective effects with silymarin 100 mg/kg, and similar nephroprotective effects with that of silymarin 100 mg/kg and metformin 250 mg/kg, respectively. Obese, hyperglycemia, hyperlipemia, steatohepatitis and related nephropathies induced by HFD supply were dramatically inhibited by 84 days of continuous treatment of all three different dosages of INJ. It is, therefore expected that INJ extracts will be a favorable alternative agent for diet-related diabetes and complications.